Dr. Daud is a highly respected researcher, and investors should be thrilled that he's presenting data.
Today's PR has a very simple meaning: It's getting close to a data-packed end of the year. It seems almost insane not to buy at these levels. ONCS is likely to be a $0.50 stock by year's end, and then trend over $1 by early next year.
Such stocks can reverse in a heartbeat. There's a lot to like in the final two months of the year.